Address correspondence to Alan Engelman,
J Virol. 2012 Apr;86(7):3861-79. doi: 10.1128/JVI.06386-11. Epub 2012 Jan 25.
Previous studies characterized two types of replication-defective human immunodeficiency virus type 1 (HIV-1) integrase mutants: class I, which are specifically blocked at the integration step, and class II, which harbor additional virion production and/or reverse transcription defects. Class I mutant enzymes supported little if any metal ion-dependent 3'-processing and DNA strand transfer activities in vitro, whereas class II enzymes displayed partial or full catalytic function in studies with simplified assay designs, suggesting that defective interaction(s) with heterologous integrase binding proteins might underlie the class II mutant viral phenotype. To address this hypothesis, class I and II mutant enzymes were interrogated under expanded sets of in vitro conditions. The majority failed to catalyze the concerted integration of two viral DNA ends into target DNA, highlighting defective integrase function as the root cause of most class II in addition to all class I mutant virus infection defects. One mutant protein, K264E, in contrast, could support the wild-type level of concerted integration activity. After accounting for its inherent reverse transcription defect, HIV-1(K264E) moreover formed preintegration complexes that supported the efficient integration of endogenous viral DNA in vitro and normal levels and sequences of 2-long terminal repeat-containing circle junctions during acute infection. K264E integrase furthermore efficiently interacted in vitro with two heterologous binding partners, LEDGF/p75 and reverse transcriptase. Our results underscore the physiological relevance of concerted integration assays for tests of integrase mutant function and suggest that the K264E mutation disrupts an interaction with an intranuclear integrase binding partner that is important for HIV-1 integration.
先前的研究描述了两种类型的复制缺陷型人类免疫缺陷病毒 1 型(HIV-1)整合酶突变体:I 类,其在整合步骤中被特异性阻断;II 类,其具有额外的病毒产生和/或逆转录缺陷。I 类突变酶在体外几乎不支持或不支持金属离子依赖性 3'加工和 DNA 链转移活性,而 II 类酶在简化的测定设计研究中显示部分或完全的催化功能,这表明与异源整合酶结合蛋白的缺陷相互作用可能是 II 类突变病毒表型的基础。为了验证这一假设,在更广泛的体外条件下对 I 类和 II 类突变酶进行了检测。大多数突变酶不能催化两个病毒 DNA 末端协同整合到靶 DNA 中,突出显示整合酶功能缺陷是除所有 I 类突变病毒感染缺陷外大多数 II 类突变病毒感染缺陷的根本原因。相比之下,一种突变蛋白 K264E 可以支持野生型水平的协同整合活性。在考虑到其固有逆转录缺陷后,HIV-1(K264E)还形成了前整合复合物,支持在体外有效整合内源性病毒 DNA,以及在急性感染期间正常水平和序列的 2 长末端重复环状接头。K264E 整合酶还在体外与两种异源结合伙伴 LEDGF/p75 和逆转录酶有效相互作用。我们的结果强调了协同整合测定在整合酶突变体功能测试中的生理相关性,并表明 K264E 突变破坏了与对 HIV-1 整合很重要的核内整合酶结合伙伴的相互作用。